Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantation | Zendy

Rosario Varela | Zendy; Goretti Vázquez Vázquez | Zendy; Víctor Noriega Concepción | Zendy; Andrea Galego García | Zendy; Concepción Andón Saavedra | Zendy

Open Access

Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantation

Author(s) -

Rosario Varela,

Goretti Vázquez Vázquez,

Víctor Noriega Concepción,

Andrea Galego García,

Concepción Andón Saavedra

Publication year - 2017

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2017.08.004

Subject(s) - abo blood group system , pure red cell aplasia , aplasia , medicine , hematopoietic stem cell transplantation , incidence (geometry) , immunosuppression , dexamethasone , transplantation , stem cell , immunology , anemia , biology , physics , genetics , optics

The literature reports an incidence of Pure Red Cell Aplasia (PRCA) ranging from 6-30% of all cases of ABO-incompatible HSCT. Although most patients resolve spontaneously after withdrawal immunosuppression, some of them require more aggressive treatment to manage this condition.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research